New science-based endpoints to accelerate oncology drug development
- 31 March 2005
- journal article
- review article
- Published by Elsevier in European Journal Of Cancer
- Vol. 41 (4) , 491-501
- https://doi.org/10.1016/j.ejca.2004.12.006
Abstract
No abstract availableKeywords
This publication has 70 references indexed in Scilit:
- Translation of pharmacogenomics and pharmacogenetics: a regulatory perspectiveNature Reviews Drug Discovery, 2004
- Monoclonal Antibodies in Cancer TherapyCurrent Medicinal Chemistry - Anti-Cancer Agents, 2004
- Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal CancerNew England Journal of Medicine, 2004
- New Treatment Options for Colorectal CancerNew England Journal of Medicine, 2004
- Colorectal cancer marketNature Reviews Drug Discovery, 2004
- Velcade®: U.S. FDA Approval for the Treatment of Multiple Myeloma Progressing on Prior TherapyThe Oncologist, 2003
- Trends in development and approval times for new therapeutics in the United StatesNature Reviews Drug Discovery, 2003
- FDA Drug Approval Summary: Gefitinib (ZD1839) (Iressa®) TabletsThe Oncologist, 2003
- The Effect of Celecoxib, a Cyclooxygenase-2 Inhibitor, in Familial Adenomatous PolyposisNew England Journal of Medicine, 2000
- Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 StudyJNCI Journal of the National Cancer Institute, 1998